Advantages and disadvantages of biodegradable platforms in drug eluting stents

Table 2 Quantitative coronary analysis for both groups in the EUCATAX trial n (%)

	PES	BMS	P value
Baseline QCA analysis	n = 169	n = 153
Reference diameter (mm)	2.75 ± 0.5	2.85 ± 0.5	0.086
Minimal luminal diameter (mm)	0.86 ± 0.4	0.85 ± 0.5	0.780
Lesion length (mm)	16.2 ± 6.1	15.6 ± 6.3	0.410
Stent diameter (mm)	21.7 ± 5.6	20.0 ± 4.8	0.160
Stent size (mm)	2.96 ± 0.4	2.93 ± 0.5	0.780
Immediately Post PCI QCA analysis
Reference diameter (mm)	2.91 ± 0.44	2.96 ± 0.43	0.340
Minimal luminal diameter (mm)	2.68 ± 0.42	2.72 ± 0.43	0.400
Follow up QCA analysis	n = 98	n = 88
Reference diameter (mm)	2.75 ± 0.48	2.75 ± 0.36	0.990
Minimal luminal diameter (mm)	2.16 ± 0.51	1.81 ± 0.75	0.007
Stenosis diameter (%)	27.4 ± 29.8	39.6 ± 23.9	0.005
Acute gain	1.82 ± 0.47	1.87 ± 0.62	0.450
Net gain	1.30 ± 0.49	0.93 ± 0.63	0.002
Late loss (in-stent)	0.52 ± 0.59	0.94 ± 0.70	0.002
Late loss (in-segment)	0.50 ± 0.56	0.91 ± 0.069	0.001
Angiographic restenosis	13 (13.2)	31 (35.2)	0.001
Follow up intravascular ultrasound analysis	n = 45	n = 37
Stent length (mm)	21.7 ± 5.6	20.0 ± 4.8	0.160
Stent size (mm)	2.96 ± 0.4	2.93 ± 0.5	0.780
Incomplete stent apposition	5 (11.1)	9 (24.3)	0.150
Proximal segment	1 (2.2)	8 (21.6)	0.015
Body segment	2 (4.4)	1 (2.7)	1.000
Distal segment	2 (4.4)	0 (0.0)	0.500

QCA: Quantitative coronary analysis; PCI: Percutaneous coronary intervention; BMS: Bare-metal stent.